Skip to main content
. 2014 Jun 2;8(6):1120–1131. doi: 10.1016/j.molonc.2014.05.009

Table 1.

Systemic therapy with activity in brain metastasis from solid tumors.

Tumor type References Cytotoxic Targeted therapy
Antiangiogenic Tyrosine kinase inhibitor Others
Breast (Rivera et al., 2006; Trudeau et al., 2006; Lin, 2013) Cyclophosphamide, fluorouracil, methotrexate, doxorubicin, capecitabine, temozolomide, etoposide, and platinum agents Bevacizumab Lapatinib
Lung (Chiu et al., 2005; De Braganca et al., 2010; Jamal‐Hanjani and Spicer, 2012; Kim et al., 2009; Wu et al., 2007; Wu et al., 2013) Cisplatin, etoposide, topotecan, temozolamide, pemetrexed, patupilone Bevacizumab Erlotinib, getifinib, crizotinib
Melanoma (Azer et al., 2014; Falchook et al., 2012; Long et al., 2012; Margolin et al., 2012; Rochet et al., 2011; van den Brom et al., 2013; Weber et al., 2011) Temozolomide, fotemustine Dabrafenib, vemurafenib Ipilimumab, interleukin‐2